Esperion Therapeutics Inc.
3891 Ranchero Drive
190 articles with Esperion Therapeutics Inc.
The collaboration for development and commercialization combines Esperion's knowledge in lipid management and Otsuka's extensive cardiovascular drug advancement and marketing in Japan.
Nexlizet is expected to be on the market in the U.S. in July 2020.
The company is planning for its drug to hit the streets by the end of March in order to provide a new option for patients with high cholesterol.
The U.S. Food and Drug Administration has a busy week planned for drug review. Here’s a look at this week’s schedule.
Replay of the webcast will be archived on the Company's website for 90 days following the event.
Esperion Announces Publication in the Journal of the American Medical Association of Bempedoic Acid Phase 3 Study 2 Results
Study 2 Demonstrated that Bempedoic Acid Significantly Lowered LDL-Cholesterol and Reduced hsCRP
Esperion Provides Bempedoic Acid Franchise Development Program Updates; Reports Third Quarter Financial Results
Esperion provided bempedoic acid franchise development program updates and financial results for the third quarter ended September 30, 2019.
Esperion Announces Pooled Analyses from Phase 3 LDL-C Lowering Development Program of Bempedoic Acid to be Presented at the American Heart Association 2019 Scientific Sessions
Esperion announced that pooled analyses from four Phase 3 clinical trials of bempedoic acid will be presented at the American Heart Association Scientific Sessions in Philadelphia on Sunday, November 17, 2019.
Esperion announced it will report third quarter 2019 financial results on November 6, 2019 before U.S. financial markets open..
Esperion announced that bempedoic acid was included in the “Top 10 Medical Innovations for 2020” at Cleveland Clinic’s 2019 Medical Innovation Summit on Wednesday, October 23rd.
9/9/2019Last week was a busy week for clinical trial results. Here’s a look at some of the top stories and reporting.
Esperion Completes Patient Enrollment in the Global CLEAR Cardiovascular Outcomes Trial for Bempedoic Acid
Esperion announced the completion of patient enrollment in the CLEAR Cardiovascular Outcomes Trial.
9/3/2019Rounding out the traditional summer months, last week had plenty of clinical trial news. Here’s a look at some of the top stories.
Esperion announced that, on August 27, 2019, the Compensation Committee of Esperion’s Board of Directors granted non-qualified stock options to purchase an aggregate of 39,500 shares of its common stock and 35,388 restricted stock units to eighteen new colleagues under Esperion’s 2017 Inducement Equity Incentive Plan.
Esperion Announces Positive Top-Line Results from Phase 2 Study of Bempedoic Acid / Ezetimibe Combination Tablet in Patients with Hypercholesterolemia and Type 2 Diabetes
Esperion announced positive top-line results from the Phase 2 bempedoic acid / ezetimibe combination tablet study.
Esperion Provides Bempedoic Acid Franchise Development Program Updates; Reports Second Quarter Financial Results
Esperion provided bempedoic acid franchise development program updates and financial results for the second quarter ended June 30, 2019.
Esperion announced that the company will participate in a lipid panel discussion with investors at the BTIG Biotechnology Conference in New York, NY on Monday, August 12, 2019 at 11:00 a.m. Eastern Time.
Esperion announced it will report second quarter 2019 financial results on August 8, 2019 before the U.S. financial markets open.
Esperion and an investor group led by Oberland Capital Management LLC announced a $200 million capped, tiered, revenue-based funding agreement on net revenues of bempedoic acid and the bempedoic acid / ezetimibe combination tablet.
Esperion announced the appointment of Tracy M. Woody as a Class I director, with a term expiring at the 2020 meeting of stockholders.